Publication | Closed Access

Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols

Hematological MalignancyElderly PatientsMedicineMixed-phenotype Acute LeukemiaHematologyPharmacotherapyOncologyAcute Promyelocytic LeukemiaEmergency Medicine